Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Deciphera Pharmaceuticals Inc
(NQ:
DCPH
)
25.59
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Deciphera Pharmaceuticals Inc
< Previous
1
2
3
4
5
Next >
Why Deciphera Pharmaceuticals Stock Jumped This Week
March 16, 2023
The company's lead therapy received an FDA Breakthrough Therapy designation.
Via
The Motley Fool
Stifel Is Bullish On This 'Competitive Late-Comer' In Gastric Cancer Space
March 16, 2023
Via
Benzinga
Where Deciphera Pharmaceuticals Stands With Analysts
March 15, 2023
Via
Benzinga
Top 5 Health Care Stocks That May Rocket Higher In Q1 2023
February 27, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Looking Into Deciphera Pharmaceuticals's Return On Capital Employed
February 08, 2023
Via
Benzinga
Earnings Outlook For Deciphera Pharmaceuticals
February 06, 2023
Via
Benzinga
The Latest Analyst Ratings for Deciphera Pharmaceuticals
January 25, 2023
Via
Benzinga
Deciphera Pharmaceuticals's Return On Capital Employed Insights
November 22, 2022
Via
Benzinga
Deciphera Earns Price Target Bump With Encouraging ESMO Presentation
September 12, 2022
Via
Benzinga
$30M Bet On Deciphera Pharmaceuticals? Check Out These 4 Stocks Insiders Are Buying
January 25, 2023
Although US stocks closed mixed on Tuesday, there were a few notable insider trades.
Via
Benzinga
Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 19, 2023
Gainers Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of special dividend and appointed Timothy Murphy to lead Illegal Trading Task Force.
Via
Benzinga
Dow Falls 200 Points; Jobless Claims Drop To 4-Month Low
January 19, 2023
U.S. stocks traded lower this morning, with the Dow Jones dropping around 200 points on Thursday.
Via
Benzinga
Why Deciphera Pharmaceuticals Stock Is Nosediving
January 19, 2023
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) shares are trading lower by 10.48% to $18.45 Thursday morning after the company announced a $125 million proposed public offering of common stock.
Via
Benzinga
Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
January 19, 2023
Gainers Tricida, Inc. (NASDAQ: TCDA) rose 37.7% to $0.1898 in pre-market trading after gaining 4% on Wednesday.
Via
Benzinga
Alcoa, H.B. Fuller And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
January 19, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 04, 2023
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
January 06, 2023
Via
Benzinga
Alibaba, XPeng, Dada Nexus And Some Other Big Stocks Moving Higher On Wednesday
January 04, 2023
U.S. stocks traded mixed, with the Dow Jones dropping around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023
January 04, 2023
Via
Benzinga
Deciphera's Stomach Cancer Treatment Shows Clinical Benefit In Subgroup Of Patients
January 04, 2023
Via
Benzinga
Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies
December 14, 2022
Via
Benzinga
Deciphera Pharmaceuticals: Q3 Earnings Insights
November 03, 2022
Deciphera Pharmaceuticals (NASDAQ:DCPH) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Outlook For Deciphera Pharmaceuticals
November 02, 2022
Deciphera Pharmaceuticals (NASDAQ:DCPH) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Where Deciphera Pharmaceuticals Stands With Analysts
September 27, 2022
Over the past 3 months, 7 analysts have published their opinion on Deciphera Pharmaceuticals (NASDAQ:DCPH) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
McDonald's Price Target Cut By This Analyst, Plus Cowen Predicts $362 For Domino's Pizza
September 27, 2022
Citigroup cut McDonald's Corporation (NYSE: MCD) price target from $275 to $246. McDonald's shares rose 0.5% to $245.00 in pre-market trading.
Via
Benzinga
SVB Leerink Maintains Outperform Rating for Deciphera Pharmaceuticals: Here's What You Need To Know
September 12, 2022
SVB Leerink has decided to maintain its Outperform rating of Deciphera Pharmaceuticals (NASDAQ:DCPH) and raise its price target from $21.00 to $25.00. Shares of Deciphera Pharmaceuticals are trading up...
Via
Benzinga
This Analyst Slashes PT On Meta Platforms, Plus Mizuho Predicts $440 For Adobe
September 12, 2022
Mizuho cut the price target for Adobe Inc (NASDAQ: ADBE) from $480 to $440. Adobe shares fell 1.3% to $389.82 in pre-market trading.
Via
Benzinga
Bristol-Myers Squibb To $87? Here Are 5 Other Price Target Changes For Monday
September 12, 2022
Atlantic Equities raised the price target on Bristol-Myers Squibb Company (NYSE: BMY) from $83 to $87. Atlantic Equities analyst Steve Chesney maintained an Overweight rating on the stock....
Via
Benzinga
4 Analysts Have This to Say About Deciphera Pharmaceuticals
August 29, 2022
Within the last quarter, Deciphera Pharmaceuticals (NASDAQ:DCPH) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022
August 29, 2022
Upgrades
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.